<DOC>
	<DOC>NCT00281593</DOC>
	<brief_summary>To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.</brief_summary>
	<brief_title>Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Male and female patients &gt;=18 years of age with Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure &gt;=95 and &lt;=119 mmHg Main Pregnant breastfeeding unwilling to use birth control during the study secondary hypertension SBP&gt;=180 mmHg DBP&gt;=120 mmHg severe renal dysfunction hepatic insufficiency stroke within the last 6 months myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months unstable or uncontrolled diabetes history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>